212 related articles for article (PubMed ID: 38252825)
1. Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis.
Wang Y; Xu Z; Wu KL; Yu L; Wang C; Ding H; Gao Y; Sun H; Wu YH; Xia M; Chen Y; Xiao H
Proc Natl Acad Sci U S A; 2024 Jan; 121(5):e2312929121. PubMed ID: 38252825
[TBL] [Abstract][Full Text] [Related]
2. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
3. Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7.
van Houtum EJH; Kers-Rebel ED; Looman MW; Hooijberg E; Büll C; Granado D; Cornelissen LAM; Adema GJ
Cell Mol Life Sci; 2023 May; 80(6):169. PubMed ID: 37253806
[TBL] [Abstract][Full Text] [Related]
4. The sialoglycan-Siglec-E checkpoint axis in dexamethasone-induced immune subversion in glioma-microglia transwell co-culture system.
Wielgat P; Czarnomysy R; Trofimiuk E; Car H
Immunol Res; 2019 Oct; 67(4-5):348-357. PubMed ID: 31741237
[TBL] [Abstract][Full Text] [Related]
5. Targeting glyco-immune checkpoints for cancer therapy.
Manni M; Läubli H
Expert Opin Biol Ther; 2021 Aug; 21(8):1063-1071. PubMed ID: 33502268
[No Abstract] [Full Text] [Related]
6. Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.
Yu Y; Peng W
Cancer Biol Med; 2023 May; 20(5):369-84. PubMed ID: 37133224
[TBL] [Abstract][Full Text] [Related]
7. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
Boelaars K; van Kooyk Y
Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
[TBL] [Abstract][Full Text] [Related]
8. SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity.
Bouti P; Blans C; Klein BJAM; Shome D; Nadafi R; Van Houdt M; Schornagel K; Verkuijlen PJJH; Roos V; Reijmers RM; Van Bruggen R; Kuijpers TW; Matlung HL
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38138970
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy.
Tang X; Sui D; Liu M; Zhang H; Liu M; Wang S; Zhao D; Sun W; Liu M; Luo X; Lai X; Liu X; Deng Y; Song Y
Int J Pharm; 2020 Nov; 590():119929. PubMed ID: 33010395
[TBL] [Abstract][Full Text] [Related]
10. Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities.
Haas Q; Markov N; Muerner L; Rubino V; Benjak A; Haubitz M; Baerlocher GM; Ng CKY; Münz C; Riether C; Ochsenbein AF; Simon HU; von Gunten S
Front Immunol; 2022; 13():996746. PubMed ID: 36211376
[TBL] [Abstract][Full Text] [Related]
11. Aptamer-Assisted Blockade of the Immune Suppressor Sialic Acid-Binding Immunoglobulin-Like Lectin-15 for Cancer Immunotherapy.
Wu Q; Wei X; Chen F; Huang M; Zhang S; Zhu L; Zhou L; Yang C; Song Y
Angew Chem Int Ed Engl; 2023 Dec; 62(52):e202312609. PubMed ID: 37955317
[TBL] [Abstract][Full Text] [Related]
12. The sialic acid-Siglec immune checkpoint: an opportunity to enhance immune responses and therapy effectiveness in melanoma.
Coccimiglio M; Chiodo F; van Kooyk Y
Br J Dermatol; 2024 Apr; 190(5):627-635. PubMed ID: 38197441
[TBL] [Abstract][Full Text] [Related]
13. Siglec and anti-Siglec therapies.
Murugesan G; Weigle B; Crocker PR
Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
[TBL] [Abstract][Full Text] [Related]
14. An Application of Tumor-Associated Macrophages as Immunotherapy Targets: Sialic Acid-Modified EPI-Loaded Liposomes Inhibit Breast Cancer Metastasis.
Meng X; Wang M; Zhang K; Sui D; Chen M; Xu Z; Guo T; Liu X; Deng Y; Song Y
AAPS PharmSciTech; 2022 Oct; 23(8):285. PubMed ID: 36258152
[TBL] [Abstract][Full Text] [Related]
15. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
16. Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9.
Chan C; Lustig M; Jansen JHM; Garcia Villagrasa L; Raymakers L; Daamen LA; Valerius T; van Tetering G; Leusen JHW
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444515
[TBL] [Abstract][Full Text] [Related]
17. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
Daly J; Carlsten M; O'Dwyer M
Front Immunol; 2019; 10():1047. PubMed ID: 31143186
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Siglec-Sialic Acid Immune Axis in Cancer: Current and Future Approaches.
Läubli H; Nalle SC; Maslyar D
Cancer Immunol Res; 2022 Dec; 10(12):1423-1432. PubMed ID: 36264237
[TBL] [Abstract][Full Text] [Related]
19. Unraveling the impact of a glyco-immune checkpoint in bone metastasis.
Läubli H
Proc Natl Acad Sci U S A; 2024 Feb; 121(9):e2400499121. PubMed ID: 38377217
[No Abstract] [Full Text] [Related]
20. Tools to study and target the Siglec-sialic acid axis in cancer.
Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]